

PATENT Attorney Reference No. 4239-61541

RECEIVER

NOV 0 8 2002

ECH CENTER 1600/000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.

Application No. 09/763,393

Filed: July 30, 2001

For: PAGE-4, AN X-LINKED GAGE-LIKE GENE

EXPRESSED IN NORMAL AND

NEOPLASTIC PROSTATE, TESTIS AND

UTERUS, AND USES THEREFOR

Examiner: To be assigned

Date: October 30, 2002

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on October 30, 2002, as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON D.C. 20231.

Susan Alpert Siegel, Ph.D.

Agent for Applicant

Art Unit: 1646

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS WASHINGTON, DC 20231

Enclosed for filing in the application referenced above are the following:

☐ Information Disclosure Statement ☐ Form 1449 and references cited thereon

The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, ZDP

By

Susan Alpert Siegel, Ph.D. Registration No. 43,121


One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

cc:

Docketing



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.

Application No. 09/763,393

Filed: July 30, 2001

For: PAGE-4, AN X-LINKED GAGE-LIKE GENE EXPRESSED IN NORMAL AND NEOPLASTIC PROSTATE, TESTIS AND

UTERUS, AND USES THEREFOR

Examiner: To be assigned Date: October 30, 2002

Art Unit: 1646

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on October 30, 2002 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON,

D.C. 20231

Susan Alpert Siegel, Ph.D. Agent for Applicant

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

RECEIVED

NOV 0 8 2002

COMMISSIONER FOR PATENTS WASHINGTON, DC 20231

TECH CENTER 1600/2900

Sir:

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS.

However, if the Patent Office determines that a fee is required for Applicants to file this Information Disclosure Statement, please charge any such fees, or credit overpayment, to Deposit

Account No. 02-4550. A duplicate copy of this Information Disclosure Statement is enclosed.

Respectfully submitted,


KLARQUIST SPARKMAN, LLP

Βv

Susan Alpert Siegel, Ph.D. Registration No. 43,121

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Facsimile: (503) 228-9446



Docket: 4239-61541

App: 09/763,393

Applicant: Pastan et al.

Filed: July 30, 2001

RECEIVED

applicant. I astan et al.

Art Unit:

V 0 8 2002

CENTER 1600/29

	AF.								
PATENT				U.S. PA	TENT DOCUMENTS			CH CENT	
Init.*	Number 5,662,907		Date	Name	Class	Sub	Filed		
			9/2/97	Kubo et al.					
	<u>-</u> -			ОТН	ER DOCUMENTS				
			expres	sed in normal	GE-1, an X chromosome-linked and neoplastic prostate, testis, p. 10757-10762, (September 19	and uter	_		
					prediction of peptide-MHC bir Immun., 11: 209-213 (1999).	nding: the	e 'human N	ИНС	
					lection and development of pep ogy, Vol. 6, pp. 329-336 (1995)		ed vaccines	to treat	
			Celis, E. et al., Induction of anti-tumor cytotoxic lymphocytes in normal humans using primary cultures and synthetic peptide epitopes, Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 2105-2109, (March 1994).						
			Celis, E. et al., <i>Identification of Potential CTL Epitopes of Tumor-Associated Antigen Mage-1 for Five Common HLA-A Alleles</i> , Molecular Immunology, Vol. 31, No. 18, pp. 1423-1430, (1994).						
			Chesnut et al., Design and Testing of Peptide-Based Cytotoxic T-Cell-Mediated Immunotherapeutics to Treat Infectious Diseases and Cancer, Vaccine Design: The Subunit and Adjuvant Approach, Chapter 38, eds. Powell, M. and Newman, M., Plenum Press, New York (1995).						
				The same of the sa	Complementary Methods for Probility Complex Molecules, J. M	_			
				ia, A., <i>Identify</i> 7-944, (May 1	ving Strategies for Immune Inte 4, 1999).	rvention,	Science, V	ol. 260,	
			Rammensee, H. et al., MHC ligands and peptide motifs: first listin 41:178-228, (1995).					g, Immunogentics,	

SAS:smm 10/30/2002 4239-61541 1105	06.doc

not in conformance and not considered. Send copy.

	Docket: 4239-61541	App: 09/763,393			
STATEMENT	Applicant: Pastan et al.				
BY APPLICANT	Filed: July 30, 2001	Art Unit:			
Sidney et al., Broadly Reactive HLA Restricted T Cell Epitopes and Their Implication for Vaccine Design, Concepts in Vaccine Development, Chapter 2, Ed. Kaufmann, S., Walter de Gryter, Berlin, New York (1996).					
Sinigaglia, F. and Hammer, J., Motifs and Supermotifs for MHC Class II Bindi Peptides, J. Exp. Med., Vol. 181, pp. 449-451, (February 1995).					
by expressed sequence ta	g database analysis, Proc. Natl.				
Vitiello, A. et al., Comparison of cytotoxic T lymphocyte responses or DNA immunization: implications on immunogenicity and in Eur. J. Immunol., 27:671-678, (1997).					
	DATE				
	Schafer, J. et al., Prediction of algorithm, EpiMatrix, Value of Vaccine Design, Cone Kaufmann, S., Walter de Sinigaglia, F. and Hammer, J., Peptides, J. Exp. Med., Vasmatzis, G. et al., Discovery by expressed sequence ta 95, pp. 300-304 (January Vitiello, A. et al., Comparison or DNA immunization: in Eur. J. Immunol., 27:671	RMATION DISCLOSURE STATEMENT Applicant: Pastan et al. BY APPLICANT Filed: July 30, 2001 Schafer, J. et al., Prediction of well-conserved HIV-1 ligands use algorithm, EpiMatrix, Vaccine, Vol. 16, No. 19, pp. 1880 Sidney et al., Broadly Reactive HLA Restricted T Cell Epitopes for Vaccine Design, Concepts in Vaccine Development, C Kaufmann, S., Walter de Gryter, Berlin, New York (1996) Sinigaglia, F. and Hammer, J., Motifs and Supermotifs for MHC Peptides, J. Exp. Med., Vol. 181, pp. 449-451, (February Vasmatzis, G. et al., Discovery of three genes specifically expressed sequence tag database analysis, Proc. Natl. 95, pp. 300-304 (January 1998). Vitiello, A. et al., Comparison of cytotoxic T lymphocyte response or DNA immunization: implications on immunogenicity at Eur. J. Immunol., 27:671-678, (1997).			

RECEIVED

NOV 0 8 2002

TECH CENTER 1600/2900